AFC
COGT icon

Ares Financial Consulting’s Cogent Biosciences COGT Stock Holding History

Ares Financial Consulting’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$697 Buy
+18
New +$630 ﹤0.01% 1056

Other funds holding COGT

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.97B AUM 30.33% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Ares Financial Consulting's COGT Position: Q2 2026 in Review

Ares Financial Consulting opened a new position in Cogent Biosciences (COGT) in Q2 2026: 18 shares worth $697. The stake represents ﹤0.01% of the portfolio and ranks #1056 among its holdings.

69 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Ares Financial Consulting held 18 shares of Cogent Biosciences worth $697 as of Q2 2026.
  • Cogent Biosciences was a new Ares Financial Consulting position in Q2 2026.
  • Cogent Biosciences made up ﹤0.01% of Ares Financial Consulting's portfolio in Q2 2026, its #1056 holding.
  • 69 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.